Novartis’ Scemblix (asciminib) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat a ...

Knowing this, it amazes me how many pharmaceutical organisations of all sizes are missing the mark on key areas of launch ...

Around 86% of clinical trials do not meet patient recruitment goals, ultimately failing to improve patient outcomes and ...

Every year, the medical community recognizes the month of November as Clostridioides difficile (C. diff) Awareness month. C. diff is a public health threat that causes around 500,000 infections every ...

AbbVie has announced that it will be acquiring Aliada Therapeutics for $1.4bn, marking a notable boost to its neuroscience ...

Major players from across the UK’s health and life sciences sector have responded to the Autumn Budget delivered by Labour ...

Generative AI platforms are revolutionizing drug discovery, driving significant biopharma dealmaking by enabling the design of innovative small-molecule and biologic drug candidates. The launch of ...

Johnson & Johnson (J&J) has shared positive results from a late-stage study of its dual-acting IL-23 inhibitor Tremfya ...

After the recent Paralympics, I can’t help but be in awe of the individuals who participated and achieved such amazing feats, despite having everyday challenges most of us can hardly comprehend. It is ...